Hearing Tracker·Financial report·Business & finance·3mo agoDemant Reports Strong Q2 Hearing Aid Growth, Raises 2026 OutlookDemant's upward-revised outlook signals continued market growth in hearing aids, which may reflect broader adoption trends relevant to clinic owners and the competitive landscape.+Save
MedWatch·Financial report·Business & finance·3mo agoDemant upgrade widely expected up to Q2 reportAn earnings upgrade at Demant would signal strong commercial momentum for Oticon's latest product line, which may influence device availability, pricing, and competitive dynamics across audiology clinics.+Save
MedWatch·Financial report·Business & finance·3mo agoPositive outlook at Demant prompts Nordea to raise its price targetDemant's strong financial outlook signals continued investment capacity in hearing aid innovation, which may influence product pipelines and market competition for clinics and dispensers.+Save
MedWatch·Financial report·Hearing aids·3mo agoDemant launch could boost the market for cosmetic hearing aidsIncreased competition in cosmetic and mainstream hearing aid segments from two of the industry's largest manufacturers could broaden patient device choice and influence pricing over time.+Save
MedWatch·Industry news·Business & finance·4mo agoDemant grew market share among US veterans in JuneShifts in the VA hearing aid market signal changing competitive dynamics among major manufacturers, with Amplifon's pending acquisition of GN Hearing poised to reshape the landscape further.+Save
MedWatch·Financial report·Business & finance·4mo agoDistrust of GN' management as Demant surges aheadThe sale of GN Hearing and Demant's rising momentum signal a potential shift in the competitive balance of the global hearing aid industry, which could affect product availability, pricing, and supplier relationships for clinics over the medium term.+Save
MedWatch·Financial report·Business & finance·4mo agoBank of America looks favorably upon Demant's launch of Oticon ZealFavorable analyst coverage of Demant signals that Wall Street views the Oticon Zeal launch as a meaningful commercial catalyst, which may influence the company's R&D investment and competitive positioning in the hearing aid market.+Save
MedWatch·Industry news·Regulatory & legal·4mo agoDemant suspends protection programs after Danish FSA orderRegulatory intervention by a national financial authority on a major hearing aid group's consumer programs signals growing scrutiny of financial practices within the hearing care industry.+Save
MedWatch·Industry news·Business & finance·4mo agoDemant has made IT security a top priority after cyberattack in 2019The 2019 Demant cyberattack was one of the costliest in the medical device sector, and its aftermath highlights the growing cybersecurity risk facing hearing technology supply chains and clinic IT infrastructure.+Save
MedWatch·Industry news·Business & finance·4mo agoMedia: Investors criticize GN board following hearing aid business saleThe exclusion of top-tier bidders from GN's hearing aid sale could reshape ownership and competition in the global hearing aid market, with downstream effects on product availability and pricing for clinics and patients.+Save
Audiology Worldnews·Industry news·Business & finance·4mo agoDemant appoints new lead of Hearing Aids so Nielsen can sharpen CEO focusLeadership restructuring at a top-three global hearing aid manufacturer can signal shifts in strategic direction — such as R&D priorities, market positioning, or partnership focus — that may eventually affect product availability and clinical options.+Save
MedWatch·Industry news·Business & finance·4mo agoDemant on track for best quarter since the turn of the millenniumDemant's record-breaking quarter signals strong market demand for the Oticon Zeal platform, which may influence product availability, competitive pricing, and the broader hearing aid market landscape.+Save
MedWatch·Financial report·Business & finance·5mo agoMorgan Stanley upgrades Demant and Sonova on positive market prospectsA Morgan Stanley upgrade signals that institutional investors expect a hearing aid market recovery, which could translate into increased R&D spending and product innovation from two of the industry's largest manufacturers.+Save
MedWatch·Industry news·Hearing aids·5mo agoDemant product stands out in new market analysisStrong investor-driven preference data for the Oticon Zeal signals meaningful competitive pressure in the premium hearing aid segment that clinic owners and dispensers should monitor when making stocking decisions.+Save
MedWatch·Financial report·Business & finance·5mo agoAnalysts see prospects for upward revision at Demant after strong 2026 startA broadly improving hearing aid market signals potentially greater investment in R&D, product innovation, and access initiatives that could shape the audiology landscape over the coming years.+Save
MedWatch·Industry news·Hearing aids·5mo agoDemant reaps rewards of a popular relaunch among US veteransSecuring a VA supply contract is a significant commercial milestone that shifts market share within the largest single hearing aid dispensing channel in the US.+Save
Audiology Worldnews·Industry news·Business & finance·6mo agoDemant completes divestment of Oticon MedicalDemant's complete exit from implantable hearing solutions reshapes the competitive landscape for bone-anchored and cochlear implant markets, potentially affecting clinician supplier choices and long-term product continuity.+Save
MedWatch·Industry news·Regulatory & legal·6mo agoDemant CEO warns about new EU AI regulationsEU AI regulation could slow the development pipeline and market availability of AI-powered hearing devices, with downstream effects on the full audiology supply chain.+Save
Hearing Tracker·Industry news·Business & finance·6mo agoDemant Names Bassel Rifai President of Hearing AidsLeadership transitions at top-five hearing aid manufacturers can influence product strategy, partnership priorities, and market direction for the broader audiology field.+Save
MedWatch·Financial report·Business & finance·6mo agoDanske Bank sees promising outlook for Demant after strong Q1Investor confidence in Demant signals continued R&D and commercial momentum for Oticon products, which may shape future device availability and competition in the hearing aid market.+Save
MedWatch·Financial report·Business & finance·6mo agoDemant delivers strong start to the year on relaunch momentumDemant's relaunch-driven momentum suggests the company is prioritizing portfolio refresh over entirely new platforms, which may affect the pace of clinically meaningful innovation in the near term.+Save
MedWatch·Industry news·Business & finance·6mo agoJyske Bank: Demant’s strong start points to high-end resultsPositive analyst coverage can reflect and reinforce investor confidence in Demant's portfolio strategy, indirectly signaling stability for the audiologists and dispensers who rely on their products.+Save
MedWatch·Industry news·Business & finance·6mo agoDemant CEO teases new launches: "Our platform is very strong"Anticipated Demant product launches could shift competitive dynamics in the premium hearing aid segment and affect dispensing choices for clinicians.+Save
MedWatch·Financial report·Business & finance·6mo agoDemant maintains guidance, sees lower-end outcome as "less likely"Demant's confidence in its growth trajectory signals continued investment capacity in hearing technology R&D and market expansion.+Save
Hearing Tracker·Financial report·Business & finance·6mo agoDemant Reports 6% Organic Growth in Q1 2026, Driven by Strong Oticon Zeal LaunchDemant's growth driven by the Oticon Zeal launch signals continued market momentum in premium hearing aids, which may influence product availability, pricing competition, and clinic purchasing decisions.+Save
MedWatch·Financial report·Business & finance·6mo agoDanske Bank sees potential focus on Demant’s miniature product launch and GN’s sale to Amplifon in interim reportA potential GN–Amplifon deal and Demant's product pipeline are market-shaping events that could alter competitive dynamics, pricing, and product availability across audiology clinics globally.+Save
MedWatch·Industry news·Hearing aids·6mo agoDemant launches Oticon Zeal through retail channels in the USInclusion of a new hearing aid in the VA contract significantly expands its reach to one of the largest publicly funded hearing healthcare populations in the US.+Save
Hearing Tracker·Financial report·Business & finance·9mo agoDemant Reports 2025 Revenue Growth but Lower Profits, Forcing Cost Cutting ProgramCost-cutting at a major hearing aid manufacturer could eventually affect product development timelines, workforce, and supply partnerships across the audiology industry.+Save
Hearing Tracker·Industry news·Business & finance·11mo agoDemant Sells EPOS to ACCO Brands to Focus Fully on Hearing HealthcareDemant's divestiture of a non-core audio brand signals a sharpened industry focus on hearing healthcare, which could accelerate product investment and affect competitive dynamics for clinics that carry Demant-affiliated brands.+Save